Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis
BackgroundMetabolic dysfunction-associated fatty liver disease [MAFLD, formerly known as nonalcoholic fatty liver disease (NAFLD)] is one of the most important causes of liver disease worldwide, while cardiovascular disease (CVD) is still one of the main causes of morbidity and mortality worldwide,...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.934225/full |
| _version_ | 1811183567473999872 |
|---|---|
| author | Wen Wen Hong Li Chunyi Wang Chen Chen Jiake Tang Mengyun Zhou Xuwei Hong Yongran Cheng Qi Wu Xingwei Zhang Zhanhui Feng Mingwei Wang |
| author_facet | Wen Wen Hong Li Chunyi Wang Chen Chen Jiake Tang Mengyun Zhou Xuwei Hong Yongran Cheng Qi Wu Xingwei Zhang Zhanhui Feng Mingwei Wang |
| author_sort | Wen Wen |
| collection | DOAJ |
| description | BackgroundMetabolic dysfunction-associated fatty liver disease [MAFLD, formerly known as nonalcoholic fatty liver disease (NAFLD)] is one of the most important causes of liver disease worldwide, while cardiovascular disease (CVD) is still one of the main causes of morbidity and mortality worldwide, and the two are closely related. This study aimed to investigate the risk of CVD incidence or CVD-related mortality (CVD mortality) in patients diagnosed with MAFLD under new concepts and new diagnostic criteria.MethodsWe searched English databases PubMed, Web of Science, Embase, and Cochrane Library for relevant literature. The language was restricted to English.ResultsBy 22 January 2022, 556 published studies were obtained through preliminary retrieval, and 10 cohort studies were included in this study. All statistical analyses were performed using Review Manager 5.2 software. Compared with the control group, patients in the MAFLD group had a significantly higher relative risk of CVD incidence or CVD mortality during the follow-up, with an RR rate of 1.95 (95% CI 1.76–2.17, p < 0.01). The incidence of CVD in the MAFLD group was more than twice that in the control group (RR 2.26, 95% CI 2.00–2.54, p < 0.01). The mortality rate of CVD was 1.57 times higher than that in the control group (RR 1.57, 95% CI 1.42–1.72, p < 0.01).ConclusionsPatients diagnosed with MAFLD alone had higher cardiovascular mortality than those diagnosed with NAFLD alone based on the available data. |
| first_indexed | 2024-04-11T09:48:54Z |
| format | Article |
| id | doaj.art-aa07a60a82be43549f51f0aab9e67f4c |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-11T09:48:54Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-aa07a60a82be43549f51f0aab9e67f4c2022-12-22T04:30:53ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-09-011310.3389/fendo.2022.934225934225Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysisWen Wen0Hong Li1Chunyi Wang2Chen Chen3Jiake Tang4Mengyun Zhou5Xuwei Hong6Yongran Cheng7Qi Wu8Xingwei Zhang9Zhanhui Feng10Mingwei Wang11Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, ChinaDepartment of Liver Diseases, Ma’anshan Fourth People’s Hospital, Ma’anshan, ChinaHangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, ChinaHangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, ChinaHangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, ChinaDepartment of Molecular and Cellular Physiology, Shinshu University School of Medicine, Nagano, JapanDepartment of Liver Diseases, Ma’anshan Fourth People’s Hospital, Ma’anshan, ChinaSchool of Public Health, Hangzhou Medical College, Hangzhou, ChinaHangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, ChinaHangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, ChinaDepartment of Neurology, Affiliated Hospital of Guizhou Medical University, Guiyang, ChinaHangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, ChinaBackgroundMetabolic dysfunction-associated fatty liver disease [MAFLD, formerly known as nonalcoholic fatty liver disease (NAFLD)] is one of the most important causes of liver disease worldwide, while cardiovascular disease (CVD) is still one of the main causes of morbidity and mortality worldwide, and the two are closely related. This study aimed to investigate the risk of CVD incidence or CVD-related mortality (CVD mortality) in patients diagnosed with MAFLD under new concepts and new diagnostic criteria.MethodsWe searched English databases PubMed, Web of Science, Embase, and Cochrane Library for relevant literature. The language was restricted to English.ResultsBy 22 January 2022, 556 published studies were obtained through preliminary retrieval, and 10 cohort studies were included in this study. All statistical analyses were performed using Review Manager 5.2 software. Compared with the control group, patients in the MAFLD group had a significantly higher relative risk of CVD incidence or CVD mortality during the follow-up, with an RR rate of 1.95 (95% CI 1.76–2.17, p < 0.01). The incidence of CVD in the MAFLD group was more than twice that in the control group (RR 2.26, 95% CI 2.00–2.54, p < 0.01). The mortality rate of CVD was 1.57 times higher than that in the control group (RR 1.57, 95% CI 1.42–1.72, p < 0.01).ConclusionsPatients diagnosed with MAFLD alone had higher cardiovascular mortality than those diagnosed with NAFLD alone based on the available data.https://www.frontiersin.org/articles/10.3389/fendo.2022.934225/fullcardiovascular disease (CVD)MAFLD (metabolic associated fatty liver disease)myocardial infarctionstroketransient ischemic attack |
| spellingShingle | Wen Wen Hong Li Chunyi Wang Chen Chen Jiake Tang Mengyun Zhou Xuwei Hong Yongran Cheng Qi Wu Xingwei Zhang Zhanhui Feng Mingwei Wang Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis Frontiers in Endocrinology cardiovascular disease (CVD) MAFLD (metabolic associated fatty liver disease) myocardial infarction stroke transient ischemic attack |
| title | Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis |
| title_full | Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis |
| title_fullStr | Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis |
| title_full_unstemmed | Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis |
| title_short | Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis |
| title_sort | metabolic dysfunction associated fatty liver disease and cardiovascular disease a meta analysis |
| topic | cardiovascular disease (CVD) MAFLD (metabolic associated fatty liver disease) myocardial infarction stroke transient ischemic attack |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.934225/full |
| work_keys_str_mv | AT wenwen metabolicdysfunctionassociatedfattyliverdiseaseandcardiovasculardiseaseametaanalysis AT hongli metabolicdysfunctionassociatedfattyliverdiseaseandcardiovasculardiseaseametaanalysis AT chunyiwang metabolicdysfunctionassociatedfattyliverdiseaseandcardiovasculardiseaseametaanalysis AT chenchen metabolicdysfunctionassociatedfattyliverdiseaseandcardiovasculardiseaseametaanalysis AT jiaketang metabolicdysfunctionassociatedfattyliverdiseaseandcardiovasculardiseaseametaanalysis AT mengyunzhou metabolicdysfunctionassociatedfattyliverdiseaseandcardiovasculardiseaseametaanalysis AT xuweihong metabolicdysfunctionassociatedfattyliverdiseaseandcardiovasculardiseaseametaanalysis AT yongrancheng metabolicdysfunctionassociatedfattyliverdiseaseandcardiovasculardiseaseametaanalysis AT qiwu metabolicdysfunctionassociatedfattyliverdiseaseandcardiovasculardiseaseametaanalysis AT xingweizhang metabolicdysfunctionassociatedfattyliverdiseaseandcardiovasculardiseaseametaanalysis AT zhanhuifeng metabolicdysfunctionassociatedfattyliverdiseaseandcardiovasculardiseaseametaanalysis AT mingweiwang metabolicdysfunctionassociatedfattyliverdiseaseandcardiovasculardiseaseametaanalysis |